Armistice Capital’s United Therapeutics UTHR Stock Holding History

Armistice Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-128,000	Closed	-$11.3M	–	101
2019 Q4	$11.3M	Sell	128,000 -102,000	-44%	-$8.98M	0.65%	46
2019 Q3	$18.3M	Sell	230,000 -94,000	-29%	-$7.57M	1.22%	33
2019 Q2	$25.3M	Buy	+324,000	New	+$30.3M	1.59%	23
2018 Q4	–	Sell	-292,000	Closed	-$37.3M	–	96
2018 Q3	$37.3M	Buy	+292,000	New	+$36.1M	2.24%	14
2018 Q2	–	Sell	-388,000	Closed	-$43.6M	–	90
2018 Q1	$43.6M	Buy	388,000 +188,000	+94%	+$23.9M	3.33%	4
2017 Q4	$29.6M	Buy	200,000 +50,000	+33%	+$6.36M	2.95%	5
2017 Q3	$17.6M	Buy	+150,000	New	+$19.2M	2.07%	12

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Armistice Capital's UTHR Position: Q1 2020 in Review

Armistice Capital sold out of United Therapeutics (UTHR) in Q1 2020, closing a stake of 128,000 shares — an estimated $11.3M sold.

Armistice Capital first reported a position in UTHR in Q3 2017 and held it in 7 quarters. The position peaked at $43.6M in Q1 2018. 303 funds tracked by Wall St. Rank hold UTHR as of Q1 2020.

Armistice Capital reported no remaining United Therapeutics position as of Q1 2020 after selling out during the quarter.
Armistice Capital sold 128,000 United Therapeutics shares in Q1 2020, an estimated $11.3M.
Armistice Capital first reported a position in United Therapeutics in Q3 2017 and held it in 7 quarters.
Armistice Capital's United Therapeutics position peaked at $43.6M in Q1 2018.
303 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2020.

Based on Armistice Capital's 13F filing for Q1 2020, filed 15 May 2020.